uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face March 13, 2026, Deadline

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for securities fraud, alleging material misstatements regarding its Huntington's disease gene therapy drug, AMT-130, during the class period from September 24, 2025, to October 31, 2025 [1]. Summary by Relevant Sections Lawsuit Details - The lawsuit was filed by Kessler Topaz Meltzer & Check, LLP on behalf of investors who purchased uniQure ordinary shares during the specified class period [1]. - The deadline for investors to seek lead plaintiff status is April 13, 2026 [1]. Allegations - The key allegations include misleading statements about the Phase I/II clinical trials of AMT-130 and the timeline for the Biologics License Application (BLA) submission to the FDA [1]. - Specific misrepresentations include the lack of full FDA approval for the study design and the downplaying of the likelihood of delays in the BLA timeline due to additional studies required [1]. Impact on Share Price - On November 3, 2025, uniQure's share price dropped by $33.40, or over 49%, from $67.69 to $34.29, following revelations about the inadequacy of the data for BLA submission [1]. Investor Actions - Investors are encouraged to file for lead plaintiff status by the deadline or contact KTMC for a free case evaluation [1]. - The lead plaintiff will represent the class in directing the litigation and selecting counsel [1].